Kimberly Lynn Blackwell, MD

Professor of Medicine
Assistant Professor in Radiation Oncology
Member of the Duke Cancer Institute
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Shammas, RL, Cho, EH, Glener, AD, Poveromo, LP, Mundy, LR, Greenup, RA, Blackwell, KL, and Hollenbeck, ST. "Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis." Journal of the American College of Surgeons 225, no. 6 (December 2017): 731-739.e1.

PMID
28985927
Full Text

Narloch, JL, Farber, SH, Sammons, S, McSherry, F, Herndon, JE, Hoang, JK, Yin, F-F, Sampson, JH, Fecci, PE, Blackwell, KL, Kirkpatrick, JP, and Kim, GJ. "Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis." Neuro-oncology 19, no. 10 (October 2017): 1391-1397.

PMID
28472527
Full Text

Ma, CX, Bose, R, Gao, F, Freedman, RA, Telli, ML, Kimmick, G, Winer, E, Naughton, M, Goetz, MP, Russell, C, Tripathy, D, Cobleigh, M, Forero, A, Pluard, TJ, Anders, C, Niravath, PA, Thomas, S, Anderson, J, Bumb, C, Banks, KC, Lanman, RB, Bryce, R, Lalani, AS, Pfeifer, J, Hayes, DF, Pegram, M, Blackwell, K, Bedard, PL, Al-Kateb, H, and Ellis, MJC. "Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research 23, no. 19 (October 2017): 5687-5695.

PMID
28679771
Full Text

Blackwell, K, Gascon, P, Jones, CM, Nixon, A, Krendyukov, A, Nakov, R, Li, Y, and Harbeck, N. "Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer." Annals of oncology : official journal of the European Society for Medical Oncology 28, no. 9 (September 2017): 2272-2277.

PMID
28637287
Full Text

Harbeck, N, Gascon, P, Jones, CM, Nixon, A, Krendyukov, A, Nakov, R, Li, Y, and Blackwell, K. "Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials." Future oncology (London, England) 13, no. 16 (July 2017): 1385-1393.

PMID
28453299
Full Text

Diéras, V, Miles, D, Verma, S, Pegram, M, Welslau, M, Baselga, J, Krop, IE, Blackwell, K, Hoersch, S, Xu, J, Green, M, and Gianni, L. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." The Lancet. Oncology 18, no. 6 (June 2017): 732-742.

PMID
28526536
Full Text

Musolino, A, Campone, M, Neven, P, Denduluri, N, Barrios, CH, Cortes, J, Blackwell, K, Soliman, H, Kahan, Z, Bonnefoi, H, Squires, M, Zhang, Y, Deudon, S, Shi, MM, and André, F. "Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy." Breast cancer research : BCR 19, no. 1 (February 10, 2017): 18-.

PMID
28183331
Full Text

Sammons, SL, Topping, DL, and Blackwell, KL. "HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles." Current cancer drug targets 17, no. 7 (January 2017): 637-649.

PMID
28359238
Full Text

Mitri, Z, Nanda, R, Blackwell, K, Costelloe, CM, Hood, I, Wei, C, Brewster, AM, Ibrahim, NK, Koenig, KB, Hortobagyi, GN, Van Poznak, C, Rimawi, MF, and Moulder-Thompson, S. "TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis." Clinical Cancer Research 22, no. 23 (December 1, 2016): 5706-5712.

Full Text

Anderson, GR, Wardell, SE, Cakir, M, Crawford, L, Leeds, JC, Nussbaum, DP, Shankar, PS, Soderquist, RS, Stein, EM, Tingley, JP, Winter, PS, Zieser-Misenheimer, EK, Alley, HM, Yllanes, A, Haney, V, Blackwell, KL, McCall, SJ, McDonnell, DP, and Wood, KC. "PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation." Science translational medicine 8, no. 369 (December 2016): 369ra175-.

PMID
27974663
Full Text

Pages